Published in Blood Weekly, December 11th, 1995
The presentation highlighted the safety and promising virus killing ability of the company's lead pathogen inactivation agents. The data were reported on October 25, 1995, by Hans J. Heiniger, D.V.M., Ph.D., Senior Vice President and Chief Scientific Officer of HemaSure, at the Blood Safety and Screening conference in Washington, D.C.
"The data reported by Dr. Heiniger represent HemaSure's substantial progress in advancing chemical inactivation technology for use in the SteriPath...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.